Loading…

A TCR mimic CAR T cell specific for NDC80 is broadly reactive with solid tumors and hematologic malignancies

Target identification for chimeric antigen receptor (CAR) T-cell therapies remains challenging due to the limited repertoire of tumor-specific surface proteins. Intracellular proteins presented in the context of cell surface HLA provide a wide pool of potential antigens targetable through T-cell rec...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2022-08, Vol.140 (8), p.861-874
Main Authors: Klatt, Martin G., Dao, Tao, Yang, Zhiyuan, Liu, Jianying, Mun, Sung Soo, Dacek, Megan M., Luo, Hanzhi, Gardner, Thomas J., Bourne, Christopher, Peraro, Leila, Aretz, Zita E.H., Korontsvit, Tanya, Lau, Michael, Kharas, Michael G., Liu, Cheng, Scheinberg, David A.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Target identification for chimeric antigen receptor (CAR) T-cell therapies remains challenging due to the limited repertoire of tumor-specific surface proteins. Intracellular proteins presented in the context of cell surface HLA provide a wide pool of potential antigens targetable through T-cell receptor mimic antibodies. Mass spectrometry (MS) of HLA ligands from 8 hematologic and nonhematologic cancer cell lines identified a shared, non-immunogenic, HLA-A*02–restricted ligand (ALNEQIARL) derived from the kinetochore-associated NDC80 gene. CAR T cells directed against the ALNEQIARL:HLA-A*02 complex exhibited high sensitivity and specificity for recognition and killing of multiple cancer types, especially those of hematologic origin, and were efficacious in mouse models against a human leukemia and a solid tumor. In contrast, no toxicities toward resting or activated healthy leukocytes as well as hematopoietic stem cells were observed. This shows how MS can inform the design of broadly reactive therapeutic T-cell receptor mimic CAR T-cell therapies that can target multiple cancer types currently not druggable by small molecules, conventional CAR T cells, T cells, or antibodies. •HLA-A*02:ALNEQIARL derived from NDC80 is a broadly presented cancer immunotherapy target with high abundance in hematologic malignancies.•CAR T cells designed for this target exhibit high sensitivity and specificity with no relevant toxicity toward hematopoietic stem cells. [Display omitted]
ISSN:0006-4971
1528-0020
1528-0020
DOI:10.1182/blood.2021012882